Latest News, Press Releases & Events

HOPE-1 Clinical Trial for SPX-101 Is Enrolling CF Patients in Canada and Europe

CYSTIC FIBROSIS NEWS TODAY by Ana Belo Van Wijk, PhD – The first patient has been enrolled and dosed in the HOPE-1 Phase 2 clinical trial evaluating Spyryx Biosciences‘ investigational drug SPX-101 as a treatment for cystic fibrosis (CF). The HOPE-1 study (NCT03229252) will take place in Alberta and Ontario in Canada, the United Kingdom, France, and Portugal. […]

Continue Reading

Spyryx Biosciences Announces First Patient Enrolled in Phase 2 Clinical Trial of SPX-101 for the Treatment of Cystic Fibrosis

DURHAM, N.C., October 18, 2017 – Spyryx Biosciences, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics to address severe respiratory diseases, today announced the first patient was dosed in the HOPE-1 study, a multinational Phase 2 clinical trial for its lead compound, SPX-101 in cystic fibrosis (CF). HOPE-1 is a 28-day study using an adaptive […]

Continue Reading